• “BPCO e Sideropenia”, no profit, interventional study, PI: Elena Corradini, 2018-2021
  • “Studio Italiano Multicentrico sulla prevalenza e l’impatto clinico della carenza di Ferro (Iron Deficiency) nei pazienti ricoverati nei reparti di Medicina Interna”,  SIMID, no profit, observational study, PI: Elena Corradini, 2018-2023
  •  “Modificazioni post-trasfusionali della funzione diastolica e sistolica del ventricolo sinistro ed incidenza di eventi cardiovascolari in pazienti talassemici trasfusione-dipendenti”, ECHOTAL, no profit, interventional study, PI: Antonello Pietrangelo, 2020-2021
  • “Effetto dell’inokitiolo in macrofagi di pazienti con Malattia della Ferroportina”, no profit, experimental study, PI: Antonello Pietrangelo, 2020-2023
  • “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, & Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria”,  MT-7117-G01, profit, phase III study, PI: Paolo Ventura, 2021-2022
  • “A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease”, MK-6024-001, profit, phase II study, PI: Antonello Pietrangelo, 2021-2022
  • “A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis” , MK-3655-001, profit, phase II study, PI: Antonello Pietrangelo, 2021-2023
  • “An Open-Label, Dose-Escalation, Dose-Finding, and Proof-of-Concept Trial of SP-420 in Subjects with Transfusion-Dependent β-thalassemia”, P-SP420-THAL-01, profit, phase II study, PI: Francesca Ferrara, 2024-2025
  •  “A Phase III, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Two-Arm Study to Evaluate the  Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants with Primary Biliary Cholangitis (PBC)”, CLIN-60190-454, profit, phase III study, PI: Antonello Pietrangelo, 2024-2025
  • The European Porphyria Registry (EPR) Protocol, no profit, observational study, PI: Paolo Ventura, 2015-ongoing
  • A Post-Authorisation Disease Registry Safety Study to Generate Data on the Long-Term Safety and Clinical Effectiveness of SCENESSE® (Afamelanotide 16mg) in Patients with Erythropoietic Protoporphyria (EPP), CUV-PASS-001, profit, post-authorisation study, PI: Paolo Ventura, 2017-ongoing
  • “Registro di malattie rare con accumulo di ferro non dovute a mutazioni del gene HFE”, Non-HFE Registry, no profit, observational study, PI: Elena Corradini, 2018-ongoing
  • “Profilo di espressione proteomica in pazienti con sovraccarico di ferro” , IRON-QP, no profit, interventional study, PI: Elena Corradini, 2021-ongoing
  • “A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)”, MT-7117-A-301, profit, phase III study, PI: Andrea Ricci, 2022-ongoing
  • “Registro globale prospettico, longitudinale, osservazionale di pazienti con porfiria epatica acuta (AHP)”, ELEVATE, profit, observational study, PI: Paolo Ventura, 2022-ongoing
  • “A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion Dependent Alpha- or Beta-Thalassemia, ENERGIZE- AG348-C-017, profit, phase III study, PI: Francesca Ferrara, 2022-ongoing
  • “A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia”, ENERGIZE-T– AG348-C-018, profit, phase III study, PI: Francesca Ferrara, 2022-ongoing
  • “A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease”, RISE UP – AG348-C-020, profit, phase II-III study, PI: Francesca Ferrara, 2023-ongoing
  • “Studio di estensione monocentrico di pazienti arruolati nello studio “Sintomi gastrointestinali dell’infezione da Sars-Cov-2: uno studio multicentrico prospettico”, GI COVID19 FOR MODENA,  no profit, observational study, PI: Elena Corradini, 2023-ongoing
  • “Analisi del contenuto cerebrale di ferro mediante tecniche di mappatura di suscettibilità magnetica in RM”, NEUROSIDE, no profit, observational study, PI: Elena Corradini, 2023-ongoing
  • “A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)”, CLIN-60190-453, profit, phase II study, PI: Antonello Pietrangelo, 2023-ongoing
  • “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria”, MT-7117-A-302, profit, phase III study, PI: Andrea Ricci, 2024-ongoing
  • “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis”, AK-US-001-0105, profit,  phase III study, PI: Elena Buzzetti, 2024-ongoing
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH), AK-US-001-0106, profit, phase III study, PI: Elena Buzzetti, 2025-ongoing
  • “Steatosi epatica associata a disfunzione dismetabolica (MASLD): storia naturale ed individuazione di predittori di outcome clinico a lungo termine”, STEATOMED, no profit, observational study, PI: Elena Buzzetti, 2025-ongoing
  • “Modelli in vitro di MASLD e studio di pathways riguardanti il metabolismo del ferro e dell’eme”, MoViMAFE, no profit, experimental study, PI: Elena Buzzetti, 2025-ongoing